Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $90000.0.

  • Celldex Therapeutics' Receivables - Net fell 8943.66% to $90000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $90000.0, marking a year-over-year decrease of 8943.66%. This contributed to the annual value of $700000.0 for FY2024, which is 7336.38% down from last year.
  • Celldex Therapeutics' Receivables - Net amounted to $90000.0 in Q3 2025, which was down 8943.66% from $90000.0 recorded in Q2 2025.
  • Celldex Therapeutics' Receivables - Net's 5-year high stood at $2.7 million during Q1 2024, with a 5-year trough of $90000.0 in Q2 2025.
  • Its 5-year average for Receivables - Net is $783263.2, with a median of $347000.0 in 2022.
  • As far as peak fluctuations go, Celldex Therapeutics' Receivables - Net surged by 120000.0% in 2024, and later crashed by 9413.3% in 2025.
  • Over the past 5 years, Celldex Therapeutics' Receivables - Net (Quarter) stood at $172000.0 in 2021, then skyrocketed by 101.74% to $347000.0 in 2022, then surged by 657.35% to $2.6 million in 2023, then tumbled by 73.36% to $700000.0 in 2024, then plummeted by 87.14% to $90000.0 in 2025.
  • Its Receivables - Net was $90000.0 in Q3 2025, compared to $90000.0 in Q2 2025 and $1.1 million in Q1 2025.